Skin-directed radiotherapy for primary cutaneous T-cell lymphomas
- Author:
Ha Un KIM
1
;
Yeon Joo KIM
;
Mi Woo LEE
;
Woo Jin LEE
;
Sang-wook LEE
;
Youngju SONG
;
Byungchul CHO
;
Si Yeol SONG
Author Information
- Publication Type:Original Article
- From:Radiation Oncology Journal 2024;42(3):228-236
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:To evaluate the efficacy and toxicities of skin-directed radiotherapy (RT) in primary cutaneous T-cell lymphoma (CTCL).
Materials and Methods:We retrospectively analyzed 57 CTCL lesions treated with skin-directed RT between January 2000 and December 2022. Lesions were categorized into three distinct groups: early-stage disease treated with local RT, advanced-stage disease treated with local RT, and advanced-stage disease treated with total skin electron beam therapy (TSEBT). Treatment outcomes, including response rates, recurrence patterns, and local progression probability, were assessed for each group.
Results:Mycosis fungoides (MF) constituted 90.9% of the advanced-stage pathologies, while CD4+ primary cutaneous small/medium T-cell lymphoproliferative disorder was common in the early stage lesions (55%). Median RT doses were 30.6 Gy, 27 Gy, and 32 Gy for the local RT with early stage, the local RT with advanced stage, and TSEBT with advanced stage, respectively. The complete response rates were high across the groups: 95.5%, 70.8%, and 90.9%, respectively. Seven local recurrences (29.2%) occurred in the local RT group with advanced stage, while seven patients (63.6%) in the TSEBT group experienced local failure. All recurrences were observed in lesions and patients with MF. Acute toxicities were mainly grade 1 or 2, with no grade 3 or higher events. No significant association between RT dose and local progression rates in MF lesions was found.
Conclusion:Skin-directed RT in CTCL is effective for local control and well-tolerated with less toxicity.
